Australia markets close in 1 hour 19 minutes

Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.1700-0.0400 (-1.81%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 596.11M
Enterprise value 3-92.25k
Trailing P/E N/A
Forward P/E 1-6.20
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)490.33
Price/book (mrq)1.06
Enterprise value/revenue 3-0.47
Enterprise value/EBITDA 70.01

Trading information

Stock price history

Beta (5Y monthly) 1.43
52-week change 325.57%
S&P500 52-week change 334.98%
52-week high 39.7600
52-week low 31.3600
50-day moving average 33.1950
200-day moving average 34.0661

Share statistics

Avg vol (3-month) 31.27M
Avg vol (10-day) 31.18M
Shares outstanding 544.29M
Implied shares outstanding 6N/A
Float 25M
% held by insiders 112.14%
% held by institutions 11.07%
Shares short (30 Aug 2021) 4408.54k
Short ratio (30 Aug 2021) 40.43
Short % of float (30 Aug 2021) 40.92%
Short % of shares outstanding (30 Aug 2021) 40.92%
Shares short (prior month 29 July 2021) 4313.79k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Mar 2021
Most-recent quarter (mrq)29 June 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-4,969.39%

Management effectiveness

Return on assets (ttm)-15.11%
Return on equity (ttm)-56.22%

Income statement

Revenue (ttm)196k
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)120k
EBITDA -9.13M
Net income avi to common (ttm)-18.13M
Diluted EPS (ttm)-0.9800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)57.72M
Total cash per share (mrq)2.22
Total debt (mrq)66k
Total debt/equity (mrq)0.12
Current ratio (mrq)25.75
Book value per share (mrq)2.05

Cash flow statement

Operating cash flow (ttm)-13.55M
Levered free cash flow (ttm)-9.35M